Results demonstrated that when patients with plaque psoriasis applied topical roflumilast once per day they reported clear skin as well as i

“In some diseases, cells lose their ability to differentiate, and reproduce more rapidly. Being able to redirect cells back to their usual l

Guselkumab, a biologic therapy that is part of a new class of agents targeting interleukin (IL)-23 without blocking IL-12, was approved in Nov. 2017 by Health Canada for the treatment of moderate to severe plaque psoriasis in adults. The new therapy is more precisely targeted than some earlier biologics, Dr. Melinda Gooderham said during an interview with DERM.city.She was a researcher involved in clinical trials of guselkumab. “It does not block interleukin12, only interleuk

“After a series of tests carried out by Dr. Satveer Mahil at St. John’s Institute of Dermatology [at King’s College, London], we determined

Canadian investigators have determined that apremilast—an oral phosphodiesterase 4 inhibitor—can be safely and effectively combined with at least one form of photosystemic, and/or biologic therapy in the treatment of patients with chronic plaque psoriasis. During a retrospective review, published online ahead of print in the Journal of Cutaneous Medicine and Surgery (July/August 2016; 20(4):313-316), researchers found that 81 patients with plaque psoriasis were treated with a